| 1.42 -0.04 (-2.74%) | 06-09 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 4.45 | 1-year : | 6.28 |
| Resists | First : | 3.81 | Second : | 5.38 |
| Pivot price | 1.68  |
|||
| Supports | First : | 1.27 | Second : | 1.06 |
| MAs | MA(5) : | 1.62 |
MA(20) : | 1.66 |
| MA(100) : | 2.57 |
MA(250) : | 4.81 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 5.1 |
D(3) : | 8.2 |
| RSI | RSI(14): 42.3 |
|||
| 52-week | High : | 17.95 | Low : | 1.27 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ PRFX ] has closed above bottom band by 34.0%. Bollinger Bands are 35.9% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 1.53 - 1.54 | 1.54 - 1.55 |
| Low: | 1.3 - 1.32 | 1.32 - 1.33 |
| Close: | 1.4 - 1.43 | 1.43 - 1.45 |
PRF Technologies Ltd. operates as a specialized pharmaceutical company, currently in the clinical development stage, with a focus on pioneering treatments that deliver sustained post-surgical pain management. Central to its pipeline is PRF-110, a distinctive clear, viscous, oil-based solution. This innovative product is engineered for direct application into surgical incisions, aiming to provide targeted and prolonged alleviation of discomfort following operations. PRF-110 is presently undergoing assessment in two pivotal Phase 3 clinical trials, specifically for individuals recovering from bunionectomy and hernia repair procedures. The company, which was originally incorporated in 2007 under the name PainReform Ltd., maintains its headquarters in Tel Aviv, Israel.
Mon, 08 Jun 2026
PRFX SEC Filings - PRF Technologies Ltd. 10-K, 10-Q, 8-K Forms - Stock Titan
Mon, 01 Jun 2026
Why Is PRF Tech Stock Falling On Monday? - Sahm
Fri, 29 May 2026
PRF Technologies (PRFX) Shares Surge Over 186% After Hours: Here's What Is Going On - Benzinga
Fri, 29 May 2026
PRF Technologies soars 215% as investors chase AI solar platform update and fresh preclinical pain-drug data - Quiver Quantitative
Thu, 28 May 2026
PRF Technologies Advances DeepSolar Predict™ Toward - GlobeNewswire
Thu, 28 May 2026
PRF Technologies (PRFX) advances AI DeepSolar Predict toward commercial launch - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - Specialty & Generic
|
|
| Shares Out | 0 (M) |
| Shares Float | 1 (M) |
| Held by Insiders | 809620 (%) |
| Held by Institutions | 6.3 (%) |
| Shares Short | 85 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -4.35e+006 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -16 % |
| Return on Assets (ttm) | 200 % |
| Return on Equity (ttm) | -38.8 % |
| Qtrly Rev. Growth | 17000 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | -117.37 |
| EBITDA (p.s.) | -68831.2 |
| Qtrly Earnings Growth | -7.5 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -4 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.02 |
| Price to Cash Flow | 0.1 |
| Dividend | 0 |
| Forward Dividend | 73680 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|